“…To that end, here, we report our objective assessment of Abbott's BinaxNOW COVID-19 Antigen Self-Test, which has among the highest usage, availability, distribution, and production rates of rapid tests and was the first lateral flow assay (LFA)-based rapid antigen test to receive U.S. FDA Emergency Use Authorization (EUA) for the home OTC setting (Shah et al, 2021a;Prince-Guerra, 2021;Pollock et al, 2021;Hodges, 2021). BinaxNOW is a SARS-CoV-2 diagnostic assay that detects the viral nucleocapsid (N) protein in samples collected by anterior nasal swab and reports a qualitative positive, negative, or invalid result (BINAXNOW COVID-19 AG CARD, n,d).…”